Recruiting Clinical Trials

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma|Mesothelioma

Estimated Enrollment: 36

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: MCC-18094

Study First Received: November 18, 2015

Last Updated: February 21, 2017

Estimated Primary Completion Date: January 2018


Primary Outcome Measures:

Objective Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)|Occurrence of Treatment Related Toxicity|Quality of Life Questionnaire Scores

Sponsors and Collaborators:

H. Lee Moffitt Cancer Center and Research Institute

Website Link:

Leave a Reply

Call Now ButtonCall Now